BULLOUS PEMPHIGOID ASSOCIATED WITH SITAGLIPTIN USE
A CASE REPORT
Keywords:
sitagliptin, dpp-iv inhibitors, bullous pemphigoidAbstract
INTRODUCTION
DPP-IV inhibitors are considered one of the safest anti-diabetes drugs given its low hypoglycemic risk and neutral effects on weight. Recently, cases of bullous pemphigoid have been reported on patients with type 2 diabetes treated with DPP-IV inhibitors.
CASE
A 70-year-old Filipino male of Chinese descent presented with pruritic eczematous papular rash on both shins. Lesions progressed to blisters in the trunk and extremities. Medical history was significant for T2DM and hypertension. He was on sitagliptin 50 mg daily (started a month prior) and losartan 50 mg daily.
CONCLUSION
We present a patient with T2DM on sitagliptin who presented with bullous pemphigoid. Physicians should be aware of this association since early detection may circumvent its progression and avert complications.
Downloads
References
*
Downloads
Published
How to Cite
Issue
Section
License
Journal of the ASEAN Federation of Endocrine Societies is licensed under a Creative Commons Attribution-NonCommercial 4.0 International. (full license at this link: http://creativecommons.org/licenses/by-nc/3.0/legalcode).
To obtain permission to translate/reproduce or download articles or use images FOR COMMERCIAL REUSE/BUSINESS PURPOSES from the Journal of the ASEAN Federation of Endocrine Societies, kindly fill in the Permission Request for Use of Copyrighted Material and return as PDF file to jafes@asia.com or jafes.editor@gmail.com.
A written agreement shall be emailed to the requester should permission be granted.